$LTGO

Goldman Sachs recommends two under-the-radar IPO stocks: Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE). LTGO, which develops non-opioid pain relief drugs, raised $345.6M in its IPO and has a market cap of $1.5B. Goldman's analyst sets a $73 price target, implying a 217% gain. BRVE focuses on hypertrophic cardiomyopathy treatments and plans Phase 3 trials next year. Both stocks have unanimous 'Buy' ratings from analysts.

Latigo Biotherapeutics (LTGO) reported Q2 2026 results, raising $397.4M in an upsized IPO. Cash reserves reached $55.0M pre-IPO. R&D expenses were $21.2M, G&A $4.6M, with a net loss of $25.8M. The company reported positive clinical trial results for onzotrigine and plans Phase 3 trials. It also initiated a Phase 2 trial for LTG-321.

Latigo Biotherapeutics (LTGO) reported a narrower Q2 loss of $(27.59) per share, a 24% improvement YoY, with no sales. The company plans to raise $256M-$288M via an IPO, offering 16M shares at $16-$18 each, listing on Nasdaq.

Latigo Biotherapeutics reported a net loss of $25.8M for 2Q 2026, matching the prior-year quarter, with a diluted net loss per share of $27.59. The company remains pre-revenue. Clinical trials for onzotrigine met key endpoints, and new trials are planned. The company expects cash runway into 2029.

Latigo Biotherapeutics reported positive pivotal trial results for onzotrigine in treating acute pain, with Phase 3 trials and data expected in 2027. The company raised $363.9M in an IPO, funding operations into 2029, but anticipates needing more capital for full development and commercialization. Risks include ongoing losses and regulatory challenges.

LTGO raised $397.4M in an IPO, extending its cash runway to 2029. The company reported positive Phase 2 trial results for onzotrigine in acute pain, with Phase 3 trials planned. Q2 2026 net loss was $25.8M, with R&D expenses slightly down year-over-year, according to its SEC filing.

Latigo Biotherapeutics, Inc. (LTGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million;

Latigo Biotherapeutics (LTGO) reported Q2 2026 results, including a $397.4M IPO, $55M cash, and a $25.8M net loss. The New England Journal of Medicine published positive data for onzotrigine, their lead pain drug. The company plans Phase 3 trials for onzotrigine and LTG-321, with topline data expected in 2H 2027.

Foresite Capital funds converted 9,041,328 derivative securities into Latigo Biotherapeutics (LTGO) common shares and bought 140,000 more at $18.00 per share on August 10, 2026, following LTGO's IPO. The funds now indirectly hold 3,414,544 LTGO shares, disclaiming beneficial ownership beyond pecuniary interest.

Latigo Biotherapeutics (LTGO) priced its IPO at $18, opened at $21, and raised $350M. LTG-001 showed 50% greater pain relief than hydrocodone in a 343-patient trial. Phase 3 trials are planned for 2026-2027. The company has $69.4M in cash and reported net losses of $109.2M in 2025.